Vindesine

Phase I evaluation in 68 humans with advanced refractory malignancies found dose-limiting neutropenia, constipation that occasionally progressed to paralytic ileus, and peripheral neuropathy at higher doses. Lower weekly or biweekly doses were better tolerated.

Phase II experience in 275 cancer patients reported manageable toxicity overall, with leukopenia and peripheral neuropathy as dose-limiting effects. Peripheral neuropathy was frequently observed and usually mild to moderate.

Human pharmacokinetic data in cancer patients showed dose-related leukopenia, neurotoxicity, constipation, alopecia, and influenza-like syndrome. These findings reinforce the drug’s toxicity profile rather than any health benefit for healthy adults.

Phase I evaluation in 68 humans with advanced refractory malignancies found dose-limiting neutropenia, constipation that occasionally progressed to paralytic ileus, and peripheral neuropathy at higher doses. Lower weekly or biweekly doses were better tolerated.

Phase II experience in 275 cancer patients reported manageable toxicity overall, with leukopenia and peripheral neuropathy as dose-limiting effects. Peripheral neuropathy was frequently observed and usually mild to moderate.

Human pharmacokinetic data in cancer patients showed dose-related leukopenia, neurotoxicity, constipation, alopecia, and influenza-like syndrome. These findings reinforce the drug’s toxicity profile rather than any health benefit for healthy adults.

Phase I evaluation in 68 humans with advanced refractory malignancies found dose-limiting neutropenia, constipation that occasionally progressed to paralytic ileus, and peripheral neuropathy at higher doses. Lower weekly or biweekly doses were better tolerated.

Phase II experience in 275 cancer patients reported manageable toxicity overall, with leukopenia and peripheral neuropathy as dose-limiting effects. Peripheral neuropathy was frequently observed and usually mild to moderate.

Human pharmacokinetic data in cancer patients showed dose-related leukopenia, neurotoxicity, constipation, alopecia, and influenza-like syndrome. These findings reinforce the drug’s toxicity profile rather than any health benefit for healthy adults.

Phase I evaluation in 68 humans with advanced refractory malignancies found dose-limiting neutropenia, constipation that occasionally progressed to paralytic ileus, and peripheral neuropathy at higher doses. Lower weekly or biweekly doses were better tolerated.

Phase II experience in 275 cancer patients reported manageable toxicity overall, with leukopenia and peripheral neuropathy as dose-limiting effects. Peripheral neuropathy was frequently observed and usually mild to moderate.

Human pharmacokinetic data in cancer patients showed dose-related leukopenia, neurotoxicity, constipation, alopecia, and influenza-like syndrome. These findings reinforce the drug’s toxicity profile rather than any health benefit for healthy adults.